drugset
drugset / Trial / NCT03606174

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

NCT03606174 ↗

Phase 2 Terminated 260 enrolled Mirati Therapeutics Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.

Timeline

Start
2018-09-11
Primary completion
2022-08-03
Completion
2022-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Enfortumab Vedotin Other / unclassified 1 mg/kg Intravenous
Subject Enfortumab Vedotin Other / unclassified 1.25 mg/kg Intravenous
Subject Nivolumab Monoclonal antibody 240 mg Intravenous
Subject Nivolumab Monoclonal antibody 480 mg Intravenous
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Subject Sitravatinib Small molecule 35 mg Oral
Subject Sitravatinib Small molecule 50 mg Oral
Subject Sitravatinib Small molecule 70 mg Oral
Subject Sitravatinib Small molecule 100 mg Oral
Subject Sitravatinib Small molecule 120 mg Oral

Indications

ureter transitional cell carcinoma urethra transitional cell carcinoma urinary bladder cancer